In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • What I appreciate the most about Emma is her human goodness and empathy. I have never felt I was just a case for her.

    Marilou
    Cervical cancer survivor

  • Cancer Commons’ scientists and doctors were very helpful in identifying possible clinical trials for our son’s rare brain tumor.

    Joan
    Mother of brain tumor patient

  • It has been extremely gratifying to see how Cancer Commons has brought clarity and greater access to this expertise through its convening and curation.

    Keith Flaherty, MD
    Cancer Commons Advisor

  • Cancer Commons helped give me peace of mind with my treatment decision. Chief scientist Emma Shtivelman’s expert, science-based opinion made such logical sense, and it also felt right in my soul.

    Ellen
    Breast cancer patient

  • In a field as complex and dynamic as molecular oncology in 2020, Cancer Commons offers an amazing opportunity for patients with advanced cancer to obtain scientifically up-to-date additional options that may improve both the length and quality of their lives, all free of charge.

    Gavin Gordon, PhD
    Molecular Pathologist

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.